Library Subscription: Guest

Current Molecular Targets for Urological Cancer

Volume 4, Issue 1, 2013, pp. 25-32
DOI: 10.1615/ForumImmunDisTher.2013008313
Get accessGet access

ABSTRACT

Clinically advanced stages of urological cancers are currently treated with conventional surgery, radiation, and chemotherapy. As for molecular targets, multiple kinase inhibitors (MKIs) and mammalian target of rapamycin (mTOR) inhibitors have already been introduced to treat advanced metastatic renal cell carcinoma, which is refractory to cytokine therapies such as interferon-α and interleukin-2. In recent trends in cancer research, the translation of basic science into clinical application has been accelerated. In this review, new molecular targets, such as MKIs, mTOR inhibitors, along with the phosphatidylinositol 3-kinase (PI3K)/ Akt signaling pathway, vascular endothelial growth factor (VEGF), and NF-κB, as well as conventional COX inhibitors, are overviewed. As the putative source of cancer oncogenesis, cancer stem cells (CSCs) have been highlighted in recent research. Current understandings of CSCs in urologic oncology are also discussed.

839 Article views 14 Article downloads Metrics
839 VIEWS 14 DOWNLOADS Google
Scholar
CITATIONS

Articles with similar content:

Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Francisco J. Padillo, Jordi Muntané, Maria A. Rodriguez-Hernandez, Elena Navarro-Villaran, Raul Gonzalez, Francisco J. Molina-Ruiz
Eliminating Cancer Stem-Like Cells in Oral Cancer by Targeting Elementary Signaling Pathways Critical Reviews™ in Oncogenesis, Vol.27, 2022, issue 4
Jigna Joshi, Bhoomi Tarapara, Apexa Pandit, Hunayna Bhavnagari, Franky Shah, Hitarth Patel
Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Anne Arah Cho, Benjamin Bonavida
Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer Journal of Environmental Pathology, Toxicology and Oncology, Vol.42, 2023, issue 1
Imran Kazmi, Mahaveer Singh, Sachin Kumar Singh, Gaurav Gupta, Dinesh Kumar Chellappan, Kamal Dua, Waleed Hassan Almalki, Sami I. Alzarea, Suman Rohilla, Fahad A. Al-Abbasi, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Elena Galvani, Godefridus J. Peters, Mina Maftouh, Elisa Giovannetti, Amir Avan
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain